Lincoln Pharmaceuticals Reports Consolidate Net Profit of Rs 36.23 Crore in Q1 FY27, Reaffirming Growth Trajectory
Lincoln Pharmaceuticals Limited has reported its consolidated operational and financial performance for the first quarter (Q1) of fiscal year 2027 (FY27), which ended on June 30, 2026. The company posted a consolidated net profit of Rs 36.23 crore in Q1 FY27, demonstrating significant growth compared to Q1 FY26.The financial results highlight the sustained performance across Lincoln Pharmaceuticals Limited and its subsidiary, Zullinc Healthcare LLP.
Financial Highlights (Consolidated)
Lincoln Pharmaceuticals saw a substantial increase in key metrics during the quarter. Total Income for Q1 FY27 stood at Rs 201.55 crore, marking a growth of 19.02% year-on-year (Y-o-Y). EBITDA reached Rs 51.70 crore, reflecting a 32.29% Y-o-Y increase compared to the Q1 FY26 figure of Rs 39.08 crore.The company's net profit grew by 30.90%, reaching Rs 36.23 crore, up from Rs 27.68 crore in Q1 FY26. Earnings Per Share (EPS) for the quarter stood at Rs 18.09 per share, a significant rise from Rs 13.82 in Q1 FY26.
The performance across the financial years is detailed below:
| Particulars | Q1 FY27 (Un-Audited) | Q1 FY26 (Un-Audited) | Y-o-Y (%) | FY26 (Audited) | FY25 | Y-o-Y (%) |
|---|---|---|---|---|---|---|
| Total Income | 201.55 | 169.34 | 19.02% | 704.48 | 645.71 | 9.10% |
| EBITDA | 51.70 | 39.08 | 32.29% | 131.14 | 123.97 | 5.78% |
| Profit before Tax | 47.55 | 35.39 | 34.36% | 115.63 | 109.19 | 5.90% |
| Net Profit | 36.23 | 27.68 | 30.90% | 87.89 | 82.35 | 6.74% |
| E.P.S (Rs.) | 18.09 | 13.82 | 30.90% | 43.88 | 41.11 | 6.74% |
Standalone Financial Results Summary
The standalone results for the quarter ended June 30, 2026, reflected strong profitability. The un-audited financial results indicated a Net Profit of Rs 3,623.45 lakh, derived from Total Income of Rs 20,154.67 lakh.Operational Strength and Future Outlook
The company continues to solidify its position in the healthcare industry, underpinned by extensive research and development capabilities. Lincoln Pharmaceuticals has developed over 600 formulations across 15 therapeutic areas. The product portfolio currently includes more than 1,700 registered products and holds 700 products under development.Lincoln Pharmaceuticals aims for a revenue target of Rs 1,000 crore over the next three years, planning to achieve an annual growth rate of 15-18%. This expansion is anticipated to be driven by robust performance in key therapeutic segments including cardiac, diabetic, dermatology, and ENT.
Globally, the company maintains a strong international presence, exporting to over 60 countries across various global markets. Future plans include expanding this footprint to 90 countries within the next two to three years. The firm has secured new approvals, including entry into Canada, EU GMP, and TGA Australia.
From an financial standing perspective, the company remains net-debt free. CRISIL Ratings reaffirmed its 'CRISIL A/Stable/CRISIL AI' rating on Lincoln Pharmaceuticals’ bank facilities. Foreign Institutional Investors (FIIs) have also increased their stake in the company to 4.60% as of June 30, 2026.
LINCOLN Stock Price Movement
As of 1:01 PM, shares of Lincoln Pharmaceuticals Limited are edging higher to ₹625, having surged by 5.42% in live trading today. The stock is seeing significant activity, supported by a strong volume of 651,889 shares exchanged during the ongoing session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.